Role of Soluble Vascular Endothelial Growth Factor Receptor-1 in the Vitreous in Proliferative Diabetic Retinopathy

Ophthalmology

Volumn 115, Issue 11, 2008, Pages 1916-1922

  Matsunaga, Nozomu ^a   Chikaraishi, Yuichi ^a   Izuta, Hiroshi ^a   Ogata, Nahoko ^b   Shimazawa, Masamitsu ^a   Matsumura, Miyo ^b   Hara, Hideaki ^a  

^a GIFU PHARMACEUTICAL UNIVERSITY   (Japan)

^b KANSAI MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

PIGMENT EPITHELIUM DERIVED FACTOR; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC RETINOPATHY; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROTEIN FUNCTION; RETINA MACULA HOLE; UMBILICAL VEIN; VITRECTOMY; VITREOUS BODY;

AGED; ANGIOGENESIS INHIBITORS; CASE-CONTROL STUDIES; COCULTURE TECHNIQUES; DIABETIC RETINOPATHY; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; ENZYME-LINKED IMMUNOSORBENT ASSAY; EYE PROTEINS; FEMALE; FIBROBLASTS; HUMANS; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; NERVE GROWTH FACTORS; RETINAL PERFORATIONS; RETROSPECTIVE STUDIES; SERPINS; UMBILICAL VEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VITREOUS BODY;

EID: 54949090327     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ophtha.2008.06.025     Document Type: Article

References (26)

1. Alon T., Hemo I., Itin A., et al. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med 1 (1995) 1024-1028
2. Gospodarowicz D., Cheng J., and Lirette M. Bovine brain and pituitary fibroblast growth factors: comparison of their abilities to support the proliferation of human and bovine vascular endothelial cells. J Cell Biol 97 (1983) 1677-1685
3. Ferrara N., Houck K., Jakeman L., and Leung D.W. Molecular and biological properties of the vascular endothelial growth factor family proteins. Endocr Rev 13 (1992) 18-32
4. Antonetti D.A., Lieth E., Barder A.J., and Gardner T.W. Molecular mechanisms of vascular permeability in diabetic retinopathy. Semin Ophthalmol 14 (1999) 240-248
5. Antcliff R.J., and Marshall J. The pathogenesis of edema in diabetic maculopathy. Semin Ophthalmol 14 (1999) 223-232
6. Kendall R.L., and Thomas K.A. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci U S A 90 (1993) 10705-10709
7. Aiello L.P., Pierce E.A., Foley E.D., et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci U S A 92 (1995) 10457-10461
8. Goldman C.K., Kendall R.L., Cabrera G., et al. Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. Proc Natl Acad Sci U S A 95 (1998) 8795-8800
9. Kong H.L., Hecht D., Song W., et al. Regional suppression of tumor growth by in vivo transfer of a cDNA encoding a secreted form of the extracellular domain of the flt-1 vascular endothelial growth factor receptor. Hum Gene Ther 9 (1998) 823-833
10. Shiose S., Sakamoto T., Yoshikawa H., et al. Gene transfer of soluble receptor of VEGF inhibits the growth of experimental eyelid malignant melanoma. Invest Ophthalmol Vis Sci 41 (2000) 2395-2403
11. Kendall R.L., Wang G., and Thomas K.A. Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. Biochem Biophys Res Commun 226 (1996) 324-328
12. Steele F.R., Chader G.J., Johnson L.V., and Tombran-Tink J. Pigment epithelium-derived factor: neurotrophic activity and identification as a member of the serine protease inhibitor gene family. Proc Natl Acad Sci U S A 90 (1993) 1526-1530
13. Dawson D.W., Volpert O.V., Gillis P., et al. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 285 (1999) 245-248
14. Stellmach V., Crawford S.E., Zhou W., and Bouck N. Prevention of ischemia-induced retinopathy by the natural ocular antiangiogenic agent pigment epithelium-derived factor. Proc Natl Acad Sci U S A 98 (2001) 2593-2597
15. Spranger J., Osterhoff M., Reinmann M., et al. Loss of the antiangiogenic pigment epithelium-derived factor in patients with angiogenic eye disease. Diabetes 50 (2001) 2641-2645
16. Gao G., Li Y., Zhang D., et al. Unbalanced expression of VEGF and PEDF in ischemia-induced retinal neovascularization. FEBS Lett 489 (2001) 270-276
17. Holekamp N.M., Bouck N., and Volpert O. Pigment epithelium-derived factor is deficient in the vitreous of patients with choroidal neovascularization due to age-related macular degeneration. Am J Ophthalmol 134 (2002) 220-227
18. Ogata N., Nishikawa M., Nishimura T., et al. Unbalanced vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor in diabetic retinopathy. Am J Ophthalmol 134 (2002) 348-353
19. Caldwell R.B., Bartoli M., Behzadian M.A., et al. Vascular endothelial growth factor and diabetic retinopathy: role of oxidative stress. Curr Drug Targets 6 (2005) 511-524
20. Funatsu H., Yamashita H., Nakamura S., et al. Vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor are related to diabetic macular edema. Ophthalmology 113 (2006) 294-301
21. Hernández C., Burgos R., Cantón A., et al. Vitreous levels of vascular cell adhesion molecule and vascular endothelial growth factor in patients with proliferative diabetic retinopathy: a case-control study. Diabetes Care 24 (2001) 516-521
22. Burgos R., Simó R., Audí L., et al. Vitreous levels of vascular endothelial growth factor are not influenced by its serum concentrations in diabetic retinopathy. Diabetologia 40 (1997) 1107-1109
23. Kobierzycka-Bala A., and Nizankowska M.H. Influence of retinal photocoagulation in patients with proliferative diabetic retinopathy on vitreous vascular endothelial growth factor concentration [in Polish]. Diabetol Dosw Klin 7 (2007) 97-102
24. Ambati B.K., Nozaki M., Singh N., et al. Corneal avascularity is due to soluble VEGF receptor-1. Nature 443 (2006) 993-997
25. Bainbridge J.W., Mistry A., De Alwis M., et al. Inhibition of retinal neovascularisation by gene transfer of soluble VEGF receptor sFlt-1. Gene Ther 9 (2002) 320-326
26. Lip P.L., Belgore F., Blann A.D., et al. Plasma VEGF and soluble VEGF receptor FLT-1 in proliferative retinopathy: relationship to endothelial dysfunction and laser treatment. Invest Ophthalmol Vis Sci 41 (2000) 2115-2119